research use only

3-Nitro-L-tyrosine Adrenergic Receptor inhibitor

Name: 3-Nitro-L-tyrosine
Brand: Selleck Chemicals
SKU: S6345
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.S6345

3-Nitro-L-tyrosine (3-NT, N-Tyr, MNT), synthesized from L-tyrosine by peroxynitrite, is a product of nitric oxide and superoxide. This compound inhibits the hemodynamic responses to angiotensin II, possibly through the inhibition of alpha 1-adrenoceptor-mediated events.

Chemical Structure

Molecular Weight: 226.19

Jump to

Quality Control

Batch: S634501 DMSO]2 mg/mL]false]Water]1 mg/mL]false]Ethanol]Insoluble]false Purity: 99.50%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS
Datasheet

99.50

Related Targets	Estrogen/progestogen Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor PGES THR
Other Adrenergic Receptor Inhibitors	Zenidolol (ICI-118551) Hydrochloride L755507 Yohimbine HCl Atipamezole Higenamine hydrochloride Detomidine HCl Naftopidil Demethyl-Coclaurine Buflomedil HCl Fenoterol hydrobromide

Solubility

In vitro
Batch:

DMSO : 2 mg/mL (8.84 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 1 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	226.19	Formula	C₉H₁₀N₂O₅	Storage (From the date of receipt)	3 years -20°C powder
CAS No.	621-44-3	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	3-NT, N-Tyr, MNT			Smiles	NC(CC1=CC(=C(O)C=C1)[N+]([O-])=O)C(O)=O

Mechanism of Action

Targets/IC₅₀/Ki	alpha 1-adrenoceptor
References	[1] https://pubmed.ncbi.nlm.nih.gov/8960880/ [2] https://pubmed.ncbi.nlm.nih.gov/8852056/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06126315	Not yet recruiting	Amyotrophic Lateral Sclerosis	Mario Negri Institute for Pharmacological Research\|University of Sydney\|FightMND	June 2024	Phase 2\|Phase 3
NCT05258669	Recruiting	COVID-19	Ocugen	February 20 2022	Phase 2\|Phase 3
NCT04259255	Active not recruiting	Amyotrophic Lateral Sclerosis\|ALS	Mitsubishi Tanabe Pharma America Inc.\|Massachusetts General Hospital	October 21 2019	--
NCT03456882	Completed	Amyotrophic Lateral Sclerosis	Mario Negri Institute for Pharmacological Research\|ALS Association\|Get out ONLUS	May 30 2017	Phase 2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):